Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenues of $4.8 billion, with solid organic revenue growth of 4% across all segments, particularly strong in the U.S. with high single-digit growth year over year [12][13] - Adjusted EBIT margin was 15%, up 30 basis points year over year, driven by volume and productivity improvements [14] - Adjusted EPS for the quarter was $1.01, reflecting a 12% increase year over year [14] Business Line Data and Key Metrics Changes - Imaging segment organic revenue grew 5% year over year, with EBIT margin up 130 basis points due to productivity and volume [16][17] - Advanced Visualization Solutions saw organic revenue increase of 3% year over year, with EBIT margin up 10 basis points [18] - Patient Care Solutions experienced 2% organic revenue growth, but EBIT margin declined by 450 basis points due to investments and product mix [19] - Pharmaceutical Diagnostics achieved 8% organic growth with an EBIT margin above 32% [20] Market Data and Key Metrics Changes - The U.S. market showed strong demand, particularly in imaging products focused on cardiology and oncology, contributing to record double-digit orders growth [6][12] - The company reported a record backlog of $20.6 billion, up $1.9 billion year over year [13] Company Strategy and Development Direction - The company is focused on strengthening its market presence and delivering a pipeline of innovations, including radiopharmaceuticals and next-generation imaging technologies [10][11] - The strategic approach includes optimizing the supply chain to mitigate tariff impacts and pursuing organic growth alongside strategic M&A opportunities [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of tariffs on profit and cash flow, estimating a total impact of $0.85 per share for 2025, with mitigation actions expected to reduce this in 2026 [10][24] - The company expects organic revenue growth for the full year 2025 to be in the range of 2% to 3%, with adjusted EPS guidance revised to between $3.90 and $4.10, reflecting a decline year over year [22][24] Other Important Information - The company announced a share repurchase program authorization of $1 billion [21] - Management emphasized the importance of maintaining R&D investments despite cost control measures in other areas [84] Q&A Session Summary Question: Tariff impact and mitigation strategies - Management detailed that the estimated tariff impact for 2025 is $0.85 per share, with mitigation strategies including duty drawback and dual sourcing to reduce future impacts [32][34] Question: China market performance and VBP impact - Management confirmed expectations of a mid-single-digit decline in China for the first half of 2025, with a sequential improvement anticipated in the second half [39][41] Question: Free cash flow reduction - The reduction in free cash flow guidance to at least $1.2 billion is attributed to tariff payments and inventory buildup [64][66] Question: Flurcato product launch and market reception - The Flurcato product is on track for a successful launch, with positive clinical feedback and expected revenue of approximately $30 million in 2025 [72][74] Question: Long-term outlook on rare earth element supply - Management expressed confidence in managing supply risks related to rare earth elements, with strategies in place for multi-sourcing [110][111]